Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Thiotepa - Adienne

Drug Profile

Thiotepa - Adienne

Alternative Names: Tepadina; Thioplex

Latest Information Update: 13 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ADIENNE
  • Developer ADIENNE; Amneal Pharmaceuticals; ESTEVE Pharmaceuticals; Gruppo Italiano Trapianto di Midollo Osseo
  • Class Antineoplastics; Aziridines; Myeloablative agonists; Organothiophosphorus compounds
  • Mechanism of Action Alkylating agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haematological disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Adenocarcinoma; Cancer metastases; Graft-versus-host disease; Haematological disorders; Lymphoma; Papilloma; Solid tumours
  • No development reported Brain cancer

Most Recent Events

  • 17 Sep 2020 No recent reports of development identified for phase-II development in Brain cancer (Combination therapy, In adolescents, In children, In infants, In neonates) in Japan (IV) (UMIN000026084)
  • 17 Sep 2020 No recent reports of development identified for phase-II development in Graft-versus-host disease (Prevention) in Italy (IV) (NCT01814488)
  • 11 May 2020 CASI Pharmaceuticals plans a registrational trial for Haematological malignancies and Inherited blood disorders in China by 2021 (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top